PBM Capital

Blue Earth Therapeutics is a radiopharmaceutical company that specializes in the advancement of next-generation targeted radiotherapeutics to treat cancer patients. It is a sister company of Blue Earth Diagnostics.

Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, focused on developing adeno-associated virus (AAV)-based therapies for monogenic diseases of the central nervous system (CNS). Founded in 2019, the company aims to create curative treatments for severe and life-threatening conditions. Its pipeline includes several product candidates, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha collaborates with The University of Texas Southwestern Medical Center to enhance its development and commercialization efforts, leveraging expertise in gene therapy to advance its mission of eradicating monogenic CNS diseases.

Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.

Xalud Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for neuro-inflammatory diseases. Established in 2009 and located in Berkeley, California, the company is advancing a gene therapy platform designed to effectively manage chronic pain and address the underlying causes of various conditions. Its lead product candidate, XT-101, is a single dosage injection aimed at halting disease progression, alleviating neuropathic pain, and reversing paralysis. Additionally, Xalud is exploring the potential of XT-101 for conditions such as multiple sclerosis and amyotrophic lateral sclerosis. The company is also conducting clinical studies with XT-150, targeting osteoarthritis pain. Through its research and development efforts, Xalud Therapeutics aims to provide significant relief for patients suffering from inflammatory joint disorders, including osteoarthritis and rheumatoid arthritis.

GenapSys, Inc. develops innovative DNA sequencing technologies aimed at enhancing applied genomic testing and medical sequencing. Its primary product, the GenapSys Sequencer, utilizes a proprietary electrical-based detection method for single nucleotide incorporations, making it suitable for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. The sequencer is designed for versatility, allowing it to operate in various lab environments and automate clonal amplification. GenapSys is also focused on collaborating with local health agencies and researchers to facilitate rapid sequencing capabilities that can aid in controlling outbreaks. Its compact design enables deployment in diverse locations, such as hospitals and public transport hubs, for efficient virus sample analysis. Founded in 2010 and headquartered in Redwood City, California, GenapSys is committed to providing accessible and precise genetic testing solutions.

SalioGen Therapeutics is a biotechnology company focused on developing innovative gene therapies for inherited disorders. Utilizing its proprietary Exact DNA Integration Technology (EDIT) platform, the company employs mammal-derived enzymes known as Saliogase to facilitate genome engineering. This approach allows for non-viral delivery of genes of any size, offering significant advantages in manufacturing and application. SalioGen's technology aims to provide safe, durable, and affordable solutions that could transform treatment options for patients with genetic conditions, while also enhancing the efficiency of cell therapy and biologics manufacturing within the healthcare sector.

PatientsLikeMe, Inc. is a healthcare data-sharing platform founded in 2004 and based in Cambridge, Massachusetts. The company enables patients to share their symptoms, treatments, and health experiences, facilitating communication among patients, caregivers, physicians, researchers, and pharmaceutical companies. With over 600,000 members, it serves as a trusted source for real-world disease information across various health conditions, including cancer, mental health, and neurological disorders. PatientsLikeMe actively collaborates with major pharmaceutical companies and government organizations to integrate the patient perspective into research and public policy. The platform not only helps individuals find new treatment options and connect with others but also contributes to the development of new therapies through shared health data. The company has published more than 100 research studies, establishing itself as a clinically robust resource in the healthcare landscape. PatientsLikeMe is a subsidiary of United Healthcare Services, Inc.

Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Livermore, California, focused on discovering and developing therapeutics and diagnostics for Alzheimer's disease and related neurodegenerative conditions. The company is advancing a targeted immunotherapy drug candidate, ACU193, which selectively targets amyloid-beta oligomers, believed to be a significant contributor to the disease process. Acumen employs a sensitivity assay to measure soluble amyloid-beta oligomer levels in cerebrospinal fluid, which aids in patient enrollment for clinical trials. The Phase 1 clinical trial for ACU193, initiated in the second quarter of 2021, aims to evaluate the drug's safety, tolerability, pharmacokinetics, and target engagement among patients with mild cognitive impairment and mild dementia due to Alzheimer's disease. Results from this trial are anticipated by the end of 2022. Founded in 1996, Acumen Pharmaceuticals is committed to developing innovative approaches to address the challenges posed by Alzheimer's disease.

Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, focused on developing adeno-associated virus (AAV)-based therapies for monogenic diseases of the central nervous system (CNS). Founded in 2019, the company aims to create curative treatments for severe and life-threatening conditions. Its pipeline includes several product candidates, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha collaborates with The University of Texas Southwestern Medical Center to enhance its development and commercialization efforts, leveraging expertise in gene therapy to advance its mission of eradicating monogenic CNS diseases.

Verona Pharma plc is a clinical-stage biopharmaceutical company based in London, dedicated to developing and commercializing innovative therapies for respiratory diseases with significant unmet medical needs. Founded in 2005, the company primarily focuses on its lead product candidate, ensifentrine, an inhaled dual inhibitor of phosphodiesterase enzymes 3 and 4, which functions as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), with additional formulations including a dry powder inhaler and a pressurized metered-dose inhaler also under development. In addition to COPD, Verona Pharma is exploring the use of ensifentrine for other respiratory conditions, including cystic fibrosis and asthma, thereby aiming to enhance the health and quality of life for patients suffering from these chronic disorders.

Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, focused on developing adeno-associated virus (AAV)-based therapies for monogenic diseases of the central nervous system (CNS). Founded in 2019, the company aims to create curative treatments for severe and life-threatening conditions. Its pipeline includes several product candidates, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha collaborates with The University of Texas Southwestern Medical Center to enhance its development and commercialization efforts, leveraging expertise in gene therapy to advance its mission of eradicating monogenic CNS diseases.

Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing innovative treatments for inherited retinal diseases. The company focuses on therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Utilizing an advanced adeno-associated virus (AAV) technology platform, including a novel spreading capsid, Atsena aims to target specific retinal conditions to prevent blindness resulting from genetic mutations. Their research is centered on providing effective ocular gene therapies that address significant challenges associated with inherited retinal diseases, with the goal of reversing or halting vision loss.

ArcherDX, Inc. is a genomics company headquartered in Boulder, Colorado, specializing in the development and commercialization of advanced genetic analysis products. Established in 2013, the company focuses on next-generation sequencing technologies to enhance genetic mutation detection, particularly in oncology. ArcherDX offers a range of research-use-only products, including DNA-based VariantPlex, RNA-based FusionPlex, and ctDNA-based LiquidPlex assays. These products enable laboratories to conduct genomic analyses for therapy optimization and cancer monitoring. Additionally, ArcherDX provides customized assay design services for clinical and biopharmaceutical clients, allowing them to target specific biomarkers and develop new applications. The company aims to deliver actionable genomic information for the treatment of solid tumors, blood cancers, and sarcomas, catering to academic laboratories, biopharmaceutical firms, and contract research organizations. ArcherDX also seeks regulatory approval for various companion diagnostic assays to further support precision medicine initiatives.

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Blacksburg, Virginia, focused on developing innovative oral therapeutics for autoimmune diseases, particularly inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. Founded in 2017, the company aims to address unmet medical needs through its unique approach to treatment, leveraging novel mechanisms of action. Its lead product candidate, NX-13, is a gut-selective NLRX1 agonist designed to modulate immune responses, and it is part of a broader pipeline that includes other internally discovered compounds targeting various pathways at the intersection of immunity and metabolism. Landos Biopharma's commitment to developing first-in-class therapeutics underscores its dedication to improving patient outcomes in the field of autoimmune disorders.

ArcherDX, Inc. is a genomics company headquartered in Boulder, Colorado, specializing in the development and commercialization of advanced genetic analysis products. Established in 2013, the company focuses on next-generation sequencing technologies to enhance genetic mutation detection, particularly in oncology. ArcherDX offers a range of research-use-only products, including DNA-based VariantPlex, RNA-based FusionPlex, and ctDNA-based LiquidPlex assays. These products enable laboratories to conduct genomic analyses for therapy optimization and cancer monitoring. Additionally, ArcherDX provides customized assay design services for clinical and biopharmaceutical clients, allowing them to target specific biomarkers and develop new applications. The company aims to deliver actionable genomic information for the treatment of solid tumors, blood cancers, and sarcomas, catering to academic laboratories, biopharmaceutical firms, and contract research organizations. ArcherDX also seeks regulatory approval for various companion diagnostic assays to further support precision medicine initiatives.

Candel Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative cancer immunotherapies aimed at improving the lives of cancer patients and their families. The company specializes in viral immunotherapies that utilize genetically modified adenoviruses and herpes simplex virus constructs to target cancer effectively. Candel's approach focuses on preventing the recurrence and progression of cancer with low toxicity, making it particularly suitable for treating less aggressive or slower-growing cancers, such as newly diagnosed prostate cancer. By enhancing treatment outcomes and facilitating faster recovery for patients, Candel Therapeutics strives to make a meaningful impact in the field of oncology.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Livermore, California, focused on discovering and developing therapeutics and diagnostics for Alzheimer's disease and related neurodegenerative conditions. The company is advancing a targeted immunotherapy drug candidate, ACU193, which selectively targets amyloid-beta oligomers, believed to be a significant contributor to the disease process. Acumen employs a sensitivity assay to measure soluble amyloid-beta oligomer levels in cerebrospinal fluid, which aids in patient enrollment for clinical trials. The Phase 1 clinical trial for ACU193, initiated in the second quarter of 2021, aims to evaluate the drug's safety, tolerability, pharmacokinetics, and target engagement among patients with mild cognitive impairment and mild dementia due to Alzheimer's disease. Results from this trial are anticipated by the end of 2022. Founded in 1996, Acumen Pharmaceuticals is committed to developing innovative approaches to address the challenges posed by Alzheimer's disease.

NanoView Biosciences is a medical technology company focused on the detection and characterization of extracellular vesicles, particularly exosomes, through its proprietary ExoView technology. Founded in 2015 and headquartered in Boston, Massachusetts, the company offers a range of products, including the ExoView R100 and ExoView Tetraspanin, as well as related kits and custom assays. NanoView's high-throughput, cost-effective analysis solutions provide life science researchers with critical insights into the biological roles of exosomes, enhancing the understanding of their potential as biomarkers for disease diagnosis, treatment, and monitoring. The company's platform is capable of analyzing nanoparticles from complex biological samples such as whole blood, serum, plasma, and urine, thereby supporting advancements in precision medicine.

ArcherDX, Inc. is a genomics company headquartered in Boulder, Colorado, specializing in the development and commercialization of advanced genetic analysis products. Established in 2013, the company focuses on next-generation sequencing technologies to enhance genetic mutation detection, particularly in oncology. ArcherDX offers a range of research-use-only products, including DNA-based VariantPlex, RNA-based FusionPlex, and ctDNA-based LiquidPlex assays. These products enable laboratories to conduct genomic analyses for therapy optimization and cancer monitoring. Additionally, ArcherDX provides customized assay design services for clinical and biopharmaceutical clients, allowing them to target specific biomarkers and develop new applications. The company aims to deliver actionable genomic information for the treatment of solid tumors, blood cancers, and sarcomas, catering to academic laboratories, biopharmaceutical firms, and contract research organizations. ArcherDX also seeks regulatory approval for various companion diagnostic assays to further support precision medicine initiatives.

Breas Medical AB specializes in designing, developing, and manufacturing homecare ventilation and sleep therapy products for both adult and pediatric patients with respiratory issues. Founded in 1991 and based in Molnlycke, Sweden, the company offers a range of medical devices, including continuous positive airway pressure devices, pressure control and support devices, life-support ventilators, and sleep apnea therapy devices. These products are intended to assist patients suffering from conditions like neuromuscular disorders, anatomical defects, and pulmonary diseases. Breas Medical also provides clinical services and distributes its products globally through a network of trained distributors and an online store. The company is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.